



Niklas Marschall leaves the Board of Qlife Holding AB

Niklas Marschall has decided to leave the Board of Qlife Holding AB and Qlife Aps with immediate effect. He has been a Board member since 2018 and thus followed the company at an early stage until the listing on Nasdaq First North Growth Market 2019 and into the present growth phase.

"It has been a fantastic journey that I am proud to have been a part of. My expertise is primarily to assist companies in the start-up phase, and that is really not Olife anymore, and therefore it is the right timing for me to hand over the baton to the team that will take Olife into the future. The Board was strengthened with new members this spring, and there is a strong plan for the company going forward. I continue to look forward to following the company's development ", says Niklas Marschall.

"Olife has benefited greatly from Niklas' experience and expertise over the past three years. He has in a very meritorious way contributed to Olife's growth and we thank him for his fine efforts and commitment", says Mette Gross, chairman of Qlife Holding AB.

Mette Gross, Chair Qlife Holding AB

E-mail: mette.gross@lehdab.com

Tel. No.: +46 (0)73-517 85 25

Qlife is a medical device company that seeks to revolutionize the clinical biomarker market for whole blood testing by taking it out of the lab and into the homes. This will facilitate easy access to blood sample results and in turn facilitate increased monitoring of parameters that enables care improvement.

Shares for Qlife are being traded on Nasdaq First North Growth Market in Stockholm with G&W Fondkommission as certified advisor (phone: +46 (0) 8-503 000 50, e-mail: ca@gwkapital.se).

Read more on Egoo.health, Qlifeholding.com or follow us on [LinkedIn](https://www.linkedin.com/company/qlife).